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The First International Conference in Systems and Network Medicine gathered together 200 global thought lead-
ers, scientists, clinicians, academicians, industry and government experts, medical and graduate students, post-
doctoral scholars and policymakers. Held at Georgetown University Conference Center in Washington D.C. on
September 11–13, 2019, the event featured a day of pre-conference lectures and hands-on bioinformatic com-
putational workshops followed by two days of deep and diverse scientific talks, panel discussions with eminent
thought leaders, and scientific poster presentations. Topics ranged from: Systems and Network Medicine in Clin-
ical Practice; the role of -omics technologies in Health Care; the role of Education and Ethics in Clinical Practice,
Systems Thinking, and Rare Diseases; and the role of Artificial Intelligence in Medicine. The conference served as a
unique nexus for interdisciplinary discovery and dialogue and fostered formation of new insights and possibilities
for health care systems advances.
Keywords: network medicine; international conference; systems; big data; artificial intelligence; ethical legal
social implications (ELSI); regulatory and health policy
Introduction
The First International Conference in Systems and Net-
work Medicine was held at Georgetown University’s
Conference Center from September 11 to 13, 2019. We
had an exciting agenda that included topics on the appli-
cation of Systems and Network Medicine in Clinical
Practice; the role of -omics technologies in Health
Care; the role of Education and Ethics in Clinical Prac-
tice, Systems Thinking, and Rare Diseases; and the role
of Artificial Intelligence in Medicine. Conference ses-
sions were deep and diverse. In addition to the talks,
we had two panel discussions covering important topics
on the challenges in the health care systems and role of
digital medicine, with eminent leaders in the field who
served as panelists.
The 3-day exciting event was hosted by Georgetown
University’s Systems Medicine Program and MedStar
Institute of Innovation and co-hosted by the Interna-
tional Association of Systems Medicine and the Euro-
pean Association for Systems Medicine. This event
would not have been possible without the help of the
generous sponsors. The goal of this article is to summa-
rize the key highlights from the conference that brought
together close to 200 attendees that included global
thought leaders, scientists, clinicians, academicians, in-
dustry and government experts, medical and graduate
students, postdoctoral scholars, and policymakers.
Day 1: Preconference Workshop
The conference began with a preconference workshop
featuring several hands-on computational sessions led
by experts in the field. The day-long learning ended
with a networking event that, among other things, ex-
posed students to potential career paths.
The preconference workshop featured two lectures
outlining the state of the science in precision theranos-
tics, which is a new field in medicine that uses specific
biological pathways in the human system and chronic
obstructive pulmonary disease (COPD) by eminent ex-
perts in the field of systems medicine, Harald H.H.W.
Schmidt, MD, PhD, PharmD, and Edwin K. Silverman,
MD, PhD. Talks were followed by hands-on computa-
tional science practice sessions for participants led by
health care systems artificial intelligence (AI) technology,
regulatory, -omics integration, and proteomic precision
medicine content experts Tavpritesh Sethi, MBBS,
PhD, IIIT, Jonathan Keeney, PhD, Elia Brodsky, CEO,
and Shuchismita Dutta, PhD.
Mechanism-based disease definitions
for precision theranostics
Harald H.H.W. Schmidt, MD, PhD, PharmD, is the
chairman of pharmacology and personalized medicine
at the School for Mental Health and Neuroscience, Maas-
tricht University, The Netherlands. Dr. Schmidt pre-
sented his perspectives on the end of medicine as we
know it stemming from his pioneering work in disease
redefinition, drug repurposing, and big data for network
pharmacology. He summarized how the current practice
of medicine depends on late diagnosis of disease by the
detection of symptoms at an organ level, but in most
cases not by a mechanistic understanding of disease.
This results in imprecise and high number to treat
approaches.
Network medicine aims to define diseases by causal
molecular mechanism allowing for precise diagnosis
and precise intervention with low numbers needed to
treat. These mechanisms are not single targets but
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signaling modules within the interactome. To fully
cover disease causality, however, our exposome and
microbiome need to be taken into account to prevent
unnecessary drug interventions where, for example,
lifestyle changes would be the most effective approach.
Network medicine will thus overcome the limitations
of symptom-based medicine that treats disease to pre-
cision medicine that cures disease.
From genetics to network medicine in COPD
Edwin Silverman, MD, PhD, is a professor of medicine at
Harvard Medical School and chief of the Channing Divi-
sion of Network Medicine at Brigham and Women’s
Hospital. He has participated in collaborative genome-
wide association studies (GWASs) that have identified
> 80 genomic regions associated with COPD; however,
the identification of functional genetic variants within as-
sociated loci remains challenging. Gene-targeted murine
models, integration of -omics data, and functional vari-
ant analyses of these GWAS regions have provided
some important insights into COPD pathogenesis. How-
ever, single genetic variants are unlikely to explain com-
plex diseases such as COPD, because perturbations of
biological networks and not isolated genes confer com-
plex disease risk. In gene expression analysis of lung
tissue samples, the top COPD GWAS loci were not
differentially expressed. However, genes that interact
with COPD GWAS genes, including HHIP, FAM13A,
and IREB2, were often differentially expressed in lung
tissue.
Using COPD GWAS genes as seed genes for random
walk analysis within the protein–protein interaction net-
work, a COPD disease network module (composed of
163 genes) was created that had significant differences in
gene expression between COPD cases and controls in
multiple disease-relevant samples. Correlation-based net-
works, gene regulatory networks, and protein–protein
interaction networks can provide complementary infor-
mation regarding complex diseases.
From complex networks to clinical
decisions with Bayesian AI
Tavpritesh Sethi, MBBS, PhD, is a physician-scientist and
assistant professor of computational biology at Indrapras-
tha Institute of Information Technology, Delhi, India; a
fellow of the Wellcome Trust/DBT India Alliance. He out-
lined how networks are the most intuitive representations
of data. However, they rely upon pairwise decisions that
limit their utility. Bayesian Decision Networks (BDNs) ex-
tend a class of probabilistic graphical models (Bayesian
Networks) through decision theory and are used regularly
in business settings. However, BDNs are underused in
clinical and public health settings due to data set complex-
ity. Dr. Sethi guided workshop participants through a
hands-on Bayesian-learning module to provide practice
with linked-open data from clinical sepsis and public
health settings. Bootstrap evaluations, quantitative infer-
encing, and optimal decision frameworks for model de-
ployment using a web-based application (R/Shiny) gave
participants an introduction to Explainable Artificial
Intelligence and Fair Accountable Transparent Machine
Learning using the open-source platform wiseR.
PrecisionFDA challenge: Creating and submitting
BioCompute objects
Jonathon Keeney, PhD, is the managing director of the
Executive Steering Committee of the BioCompute Pub-
lic Private Partnership and an assistant research profes-
sor at George Washington University. BioCompute is a
mechanism to record and communicate entire bioinfor-
matic workflows. BioCompute partitions information
in the workflow into conceptually meaningful catego-
ries, including both space for high-level overview in
the form of free text, and granular details, such as soft-
ware version numbers and parameters. BioCompute
takes guesswork out of communication, outlines a
structure for a more predictable flow of information,
and substantially improves the ability to communicate
bioinformatics analysis pipelines, thus allowing them
to be clearly understood and easily reproduced by oth-
ers. An instance of a bioinformatic workflow (scripts,
codes, processes, gene variant annotations, etc.), that
is created in a way that adheres to the BioCompute
specification, is called a ‘‘BioCompute Object’’ or BCO.
PrecisionFDA is a platform hosted by the U.S. Food and
Drug Administration (FDA) that allows users to develop
their own bioinformatic workflows and submit BCOs
and associated tools for FDA review. Dr. Keeney walked
participants through the process of choosing an existing
workflow from literature, and capturing and creating a
BCO from it using a free online tool called the BCO Editor.
In addition to Dr. Keeney, Dr. Raja Mazumder, PhD, from
George Washington University, Mr. Hadley King from
George Washington University, and Ms. Holly Stephens
from PrecisionFDA contributed to the presentation.
From data to interpretation-mining data
for answers about health and disease
Elia Brodsky, MBA, is the cofounder and CEO of Pine
Biotech, a company that merges big -omics data analysis
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with clinical care applications and real-world evidence.
Multiple integration is providing valuable insights into
molecular subtypes of various diseases. The methodolo-
gies behind integration, feature selection, and interpreta-
tion of -omics data is evolving rapidly.
Mr. Brodsky guided participants through several ex-
amples of multiomics data integration, including geno-
mic, transcriptomic, proteomic, metabolomic, and
microbiome information, for several selected diseases.
Specific examples included gene expression patterns
in breast cancer and miRNAs in hepatocellular carci-
noma (HCC). A number of specific analytic methods
and machine learning techniques for -omics data inte-
gration were reviewed, including principal component
analysis, factor regression analysis, decision trees, ran-
dom forests, bagging and bootstrapping, two-way or-
thogonal partial least squares analysis, and partial
least squares analysis. Key aspects of data processing
were summarized and known factors impacting repro-
ducibility and validation were discussed.
Molecular medicine
with three-dimensional insights
Shuchismita Dutta, PhD, is the scientific educational de-
velopment lead at Research Collaboratory for Structural
Bioinformatics Protein Data Bank (RCSB PDB), and
associate research professor at the Institute for Quantita-
tive Biomedicine at Rutgers University, NJ. She intro-
duced participants to the biomolecular structural data,
tools, and resources available from RCSB PDB.
Vast amounts of heterogeneous data spanning geno-
mics, proteomics, metabolomics, transcriptomics, and
digital health information enables personalized assess-
ments and provide management options for the practice
of precision medicine. Visualization of three-dimensional
(3D) shapes and interactions of key molecules involved in
disease processes can help facilitate multidisciplinary col-
laboration to present novel insights about diseases and
guide the design of new therapeutic rationales. The PDB
provides access to experimentally determined 3D struc-
tures for > 155,000 biological macromolecules and their
various complexes. Workshop participants were intro-
duced to freely available PDB tools and resources to visu-
alize, explore, and analyze molecular structures.
Participants gained experience with the identification
of macromolecules and small molecules contributing to
the development of a number of diseases, including sickle
cell disease, type 2 diabetes, and lung adenocarcinoma.
Day 1 concluded with a networking event organized by
Dr. Caleb McKinney, assistant dean of graduate and
postdoctoral training and development, Georgetown
University Medical Center. This event was attended by
medical and graduate students and postdoctoral scholars.
We would like to acknowledge the contributions of the
special guests to this event: Ms. Alyssa Parks, Lupus
Foundation of America, Dr. Dawn Beraud, National
Institutes of Health, Ms. Jaclyn Levy, Infectious Society
of America and, Ms. Taylor Schulte, Georgetown Univer-
sity to the event.
Day 2: Plenary Talks, Keynote Addresses, Panel
Discussions, and Session Talks
The day began with morning prayers offered by Fr.
Jerry Hayes, SJ, director of Ignatian programs, Office
of Mission and Ministry, Georgetown University. This
was followed with a welcome message by conference
chair, Dr. Sona Vasudevan, director of Georgetown
University Medical Center’s Systems Medicine Program
and professor, department of biochemistry and molec-
ular cellular biology. Dr. Vasudevan extended a warm
welcome to all the delegates on behalf of the organizing
committee, both local and international, for valued con-
tributions and participation to make the conference a
great success! Dr. Vasudevan’s message was followed
by Dr. Elliott Crooke, senior associate dean of faculty
and academic affairs, Georgetown University’s Medical
Center, who thanked the attendees for coming.
Plenary session 1, address 1: ‘‘Health informatics:
systems medicine for the 21st century’’
Doug Fridsma, MD, PhD, FACP, FACMI, the president
and CEO of American Medical Informatics Associa-
tion, opened the session with a plenary talk providing
a 360 view of current health care challenges, role of in-
formatics, and the need for systems-level integration.
Dr. Fridsma put the patient experience at the center
while speaking about the role of informatics for clini-
cians, businesses, and health care organizations. He
presented compelling cases showing that health infor-
matics has matured to the point that a new breed of
health IT professionals needs to emerge.
These professionals will not only need to be adept at
data management, but will also need to understand the
science of extracting information from data that will
empower patients. Creating value for patients will
also empower entrepreneurs to create products and
services that patients will use to make decisions about
their own health. Finally, Dr. Fridsma alluded to chal-
lenges in a rapidly changing world where data owner-
ship and rights will become increasingly important.
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The plenary session ended on a highly positive note
with the audience enthralled with the opportunities that
lie ahead in applying Systems Medicine approaches to
deliver better health care.
Plenary session 1, address 2: ‘‘Network medicine:
approach to the definition, diagnosis,
and treatment of disease in the era
of precision medicine’’
Joseph Loscalzo, MD, PhD, gave the second plenary
talk. Dr. Loscalzo is a professor at Brigham and Wom-
en’s Hospital, Harvard Medical School, and a pioneer
of Network Medicine.
Dr. Loscalzo began his plenary lecture by placing re-
cent biomedical advances in a historical context. Since
the 19th century, clinicians and biomedical researchers
have used the Cartesian reductionist approach to study
human biology, disease, and therapeutics. He stated
that although the success of this strategy is indisputable,
it has major shortcomings, including most importantly
oversimplification of complex biological phenomena.
Until recently, the prospect of unraveling that complex-
ity in a more integrative way has been limited by re-
stricted data sets and inadequate analytical approaches.
Dr. Loscalzo identified that biomedicine is now, how-
ever, poised to explore rigorously integrative system
responses that govern pathophenotype, or pathology as-
sociated with a particular disease. He outlined how
rapid growth in large genomic data sets and detailed
phenotyping coupled with the rapid expansion of quan-
titative approaches to their network-based analysis pro-
vide a unique opportunity by which to define the
response of biological systems to normal, pathological,
and therapeutic perturbations.
Biomedical science is, therefore, now positioned to
explore pathobiological complexity directly. He provided
evidence on how the new field of network medicine,
which applies systems biology and network science ap-
proaches to the dissection of molecular pathobiology
and treatment, offers a truly novel path toward (re)de-
fining and treating human disease in the modern era,
and facilitates the trajectory of true precision medicine.
Session 1: Systems/network medicine
in clinical practice
Systems medicine in immune-mediated disease: Op-
portunities for drug discovery and molecular classifica-
tion of disease (keynote address). Timothy R.D.J.
Radstake, MD, PhD, from University Medical Center,
Utrecht, The Netherlands, presented his group’s highly
impactful work of setting the stage for use of large co-
hort studies and realization of the breadth of -omics in-
tegration and clinical utility. Dr. Radstake presented
pathbreaking research from his group in autoimmune
diseases such as scleroderma. The talk focused on learn-
ing complex immune networks from large patient co-
horts in 15 different diseases and their validation
through meta-analyses. The key underpinning of his
talk was the integration of information across multio-
mic layers to arrive at clinically predictive and explain-
able mechanisms learned from > 2000 patients. These
mechanisms are largely shared across many diseases
and could relate back to the intermediate pathopheno-
types alluded to earlier in the day.
Dr. Radstake’s talk also highlighted the need for
reclassifying diseases through molecular networks
that permeate different immune cells, including T
cells, B cells, monocytes, and myeloid and plasmacy-
toid dendritic cells. The common emphasis on shared
etiological features rather than shared phenotypic pre-
sentations in two different specialties, that is, cardiol-
ogy and rheumatology, underscored the integrative
nature of Systems Medicine that cuts across disciplines.
Precision medicine in respiratory disease: Are we be-
yond fiction? Anke-Hilse Maitland-Van Der Zee,
PhD, from Amsterdam University Medical Centers,
The Netherlands, discussed upcoming computational
approaches such as Similarity Network Fusion (SNF)
analysis, which allows for the integration of diverse
sets of information from various -omics and clinical lay-
ers to stratify asthma patients. The impactful work on
disentangling asthma subphenotypes further revealed
that it was possible to achieve higher statistical signifi-
cance despite small sample sizes by using SNF instead
of reductionist approaches. She also showed the rich in-
formation content within convenient to obtain matrices
such as exhaled breath, thus democratizing the use of
systems approaches for clinics without the need for
complex biopsies or invasive tests.
Network medicine, risk stratification, and pulmonary
hypertension. Bradley A. Maron, MD, from Brigham
and Women’s Hospital, Harvard Medical School, then
spoke about unexplained dyspnea as a harbinger of pul-
monary hypertension and the opportunity for early de-
tection offered by the networks approach that he
developed. In this clinical study, Dr. Maron collected
and used invasive cardiopulmonary testing data to con-
struct a correlation network.1 From the exercise network,
Kurnat-Thoma, et al.; Systems Medicine 2020, 3.1
http://online.liebertpub.com/doi/10.1089/sysm.2020.0001
26
a subnetwork was developed that included peak volume
of oxygen consumption and nine other variables.
Information from the subnetwork yielded clusters
that were predictive of subsequent clinical events, and
in this regard outperformed standard prediction analy-
sis methods such as logistic regression. This networks-
based feature selection led to clinical utility in the form
of a point-of-care risk stratification calculator for pa-
tients with exercise intolerance. Most importantly, the
findings of networks-driven risk score were validated
in two cohorts across different continents (North
America and Europe) for predicting hospitalization in
patients with unexplained exercise intolerance.
Applying network medicine to change the way patients
with autoimmune diseases are treated. Alif Saleh,
MS, continued the theme of network-based subpheno-
type discovery. Mr. Alif Saleh’s talk emphasized early
detection of nonresponders to first-line antitumor ne-
crosis factor (ANF) therapy for autoimmune disease
treatment. Mr. Saleh, who is the CEO of Scipher Med-
icine Corporation, described the health and economic
costs associated with failure of ANF therapies. He fur-
ther demonstrated how Scipher Medicine’s network-
based approaches identify response gene expression
signatures and predict nonresponders with high accu-
racy. Being able to identify nonresponders and putting
them on right alternative therapy from day 1, improves
patient outcome and saves significant amount of dol-
lars currently wasted in ineffective therapy.
Systems research, clinical practice and management:
The Italian road to systems medicine. Christian Pris-
tipino, MD, gave the final talk of this session. It was a
tour de force of the Italian Road to Systems Medicine
as choreographed by Dr. Christian Pristipino, found-
ing president of Italian Association of Systems Medi-
cine (ASSIMSS). He unveiled the extraordinary
convergence of 26 experts from medicine, nursing,
systems science, psychology, epistemology, manage-
ment, pedagogy, and sociology to lay the foundation
of Systems Medicine in Italy. This truly interdisciplin-
ary group is attacking siloed approaches to medicine
by integrating systems thinking in the three main as-
pects of real-world medicine: research, clinical care,
and health care systems management.
Dr. Pristipino described the functioning of this most
unlikely convergence through a well-defined structure
of the organization that works through mixed working
groups and task groups. Together, members are en-
gaged in deep scientific advances such as the effect of
quantum approaches, fuzzy inductive reasoning and
network science to advance the delivery of Systems
Medicine. The importance of clinical engagement
with the patients as the center of care was also a key
theme in Dr. Pristipino’s talk, who emphasized the
need for an all-around growth and collaborative mind-
set to ensure sustainability of medicine.
Session 2: -omic technologies
and complex diseases
Toward clinical decision support in oncology: Identify-
ing driver alterations and therapeutic options (keynote
address). Nikolaus Schultz, PhD, from Memorial
Sloan Kettering Cancer Center discussed oncological
clinical decision support applications where clinical
sequencing of tumors becomes a mainstream in can-
cer care. He discussed the various tools developed by
his group for clinical support and how they helped iden-
tify the implications of specific mutations. Specific appli-
cations highlighted included the Cancer Hotspots
database for single residue and in-frame indel mutation
hotspots, OncoKB Precision Oncology Knowledge Base,
and the cBioPortal for Cancer Genomics.2–5 It was stated
that > 42,000 of their institution’s sequenced tumor
samples were profiled by using these innovative and
state-of-the-art tools, which represents a milestone in
clinically relevant oncogenomics.
Comparative oncogenomics of liver disease: The sex
matters. Damjana Rozman, PhD, from University of
Ljubljana, Slovenia, presented how biological sex is
an under-represented variable in liver pathologies.
Her laboratory developed a mouse knockout with di-
minished cholesterol synthesis with a deleted CYP51
gene. Novel substantial differences between female
and male liver metabolism and gene expression pat-
terns in HCC were discovered.
Specifically, female mice subgroups of HCC tran-
scriptomes contained disbalanced cholesterol metabo-
lism profiles, which were confirmed in human HCC
transcriptome public databases. Disbalanced cholester-
ol metabolism was a risk factor for sex-dependent liver
damage and more aggravating disease phenotypes in
females. Identification of these trends opens venues to-
ward personalized approaches in liver disease interven-
tion strategies.
Metabolomic biomarkers predictive of radiation late ef-
fects. Amrita Cheema, PhD, of Georgetown Univer-
sity, Washington, DC, discussed the value of metabolomic
Kurnat-Thoma, et al.; Systems Medicine 2020, 3.1
http://online.liebertpub.com/doi/10.1089/sysm.2020.0001
27
markers to assess the late effects of radiation therapy in
a cohort of prostate cancer patients that received treat-
ment at Medstar Georgetown University Hospital.
Findings from this initiative helped delineate robust
biomarkers that predict radiation toxicity, including
proctitis and tumor recurrence with high specificity
and sensitivity. Radiation metabolomics was presented
as a stand-alone technology to understand the molecu-
lar basis of perturbations due to radiation late effects.
Panel discussion 1: Technology and regulation
of digital medicine
Panel 1 was moderated by Robert Jarrin, JD, an adjunct
assistant professor at Georgetown University School of
Medicine. Panelists included Kapil Parakh, MD, ad-
junct assistant professor of medicine, Yale University,
New Haven, CT and Medical Lead, Google Fit, Google,
LLC; Sylvia Trujillo, MPP, JD, senior Washington
Counsel, Life Sciences/Digital Medicine, The American
Medical Association (AMA), Washington, DC; Pat
Baird, MBA, head of Global Software Standards, Phi-
lips, Pleasant Prairie, WI; Bakul Patel, MBA, associate
director for Digital Health, Center for Devices and
Radiological Health, FDA, Silver Spring, MD.
The panel discussed current policy and regulatory
developments in the exciting field of digital health and
medicine. Topics included FDA regulation of digital
medical devices, Medicare reimbursement for remote
physiological monitoring treatment management ser-
vices, Current Procedural Terminology (CPT) coding
of medical professional digital health services, and ad-
vances in technology, including AI and machine learn-
ing in Systems Medicine.
Panelists began by answering two simple questions:
what is digital health and what is digital medicine?
Mr. Patel spoke of FDA’s institutional investments to
bolster agency expertise in this evolving area, both in-
ternally across FDA and externally through industry
and patient engagement. He addressed the nexus be-
tween medical device interoperability, privacy, security,
and health information technologies and informatics.
Ms. Trujillo gave an overview of AMA’s roles in ad-
vancing the adoption of digital medical technologies
while ensuring their safety, efficaciousness, and equity.
Dr. Parakh discussed the regulatory challenges that
come from rapid evolution of technology as well as the
importance of incorporating scientific evidence into digi-
tal health products. Mr. Baird provided an overview of the
rigor behind technological standards specific to digital
health and Systems Medicine. He argued that although
standards are widely adopted, common challenges are
not technological but rather rooted in design and usability
flaws. The panel discussion was well received with several
stimulating questions asked by the audience.
Session 3: Ethics and educational considerations
in the era of precision medicine
Ethics, education, and organization of health services in
the era of big data (keynote address). Igor Svab, MD,
presented insights from the department of family med-
icine, University of Ljubljana, Slovenia. Dr. Svab out-
lined how big data poses considerable challenge to the
profession of medicine and the health care system.
There is a need for new educational directions, ethical
considerations and structures for health care service de-
livery as greater numbers of personal genomes are inte-
grated into various clinical specialties and health care
service payment structures. New team compositions
with greater participation of genetics counselors, bioin-
formaticians, and health data security experts must be
achieved. Core educational content for clinicians in pri-
mary care and hospital settings across various medical
specialties outlining minimum competence standards
in the context of continuously evolving large-scale
data complexities must be defined. Currently practicing
providers must develop solutions for integrating new
complex genomic diagnostic tools into routine clinical
investigation. Integral to moving forward is the unified
dialogue between specialist experts, medical providers,
and allied health care professionals to use these ad-
vances to better patient care.
Big data, brain science, and neuroethics:
Expanding possibilities, addressing
the problematic
James Giordano, PhD, from Georgetown University
Medical Center addressed how big data approaches,
combined with neuroscientific and neurotechnological
advances, foster enhanced capacity to derive new in-
sights to the structure and functions of the brain. Such
capability affects definitions and meanings of normality
and abnormality, health and disease, and the medical,
social, economic, and legal regard, and treatment that
these definitions evoke. In this light ethicolegal consider-
ation of neuroscientific applications of big data must
be carefully considered.
His team posits that effective ethical analysis and en-
gagement of big data-dependent efforts in neuroscience
require (1) assessment of actual capabilities and limits of
neuroscientific and computational tools and techniques;
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(2) recognition of the ways that these methods, technolo-
gies, and outcomes can impact society—locally and inter-
nationally; and (3) a dialectic approach that is sensitive
and responsive to cultural, philosophical, and ethical val-
ues and perspectives so as to develop a synthetic ethical
framework for informing and guiding research, use(s)-
in-practice, and relevant international policy.
An ethical framework for the use of consumer
generated data in health care
Jessica Skopac, PhD, JD, MA, a health policy analyst
with the MITRE Corporation, outlined how consumer-
generated data (CGD; e.g., social media use, Internet
searches, buying behaviors, and memberships) are in-
creasingly being used in predictive health care utiliza-
tion analytics. The absence of ethical standards that
clarify best practices presents implications for patient
privacy and autonomy, trust-based patient–provider
relationships, and could marginalize at risk individuals
and populations.
Her team used a modified Delphi method to review
U.S. and international CGD policies, health care ethics,
ethical applications for analytics, algorithms, and ma-
chine learning to develop a final conceptual model, in-
cluding five values (individual self-determination,
health, distributive justice, trustworthiness, and priva-
cy); eight principles (respect autonomy, consider fair-
ness, ensure accountability, empower individuals and
communities, preserve data security, promote data pro-
tection, promote transparency, and consider individual
and population health); and 39 user-specific guidelines.
For the framework to be flexible and broadly applicable
to various situations, the values and principles are not
articulated in any hierarchical order of importance,
but rather require fact-finding and deliberation to de-
termine whether the ethical permissibility of potential
actions might involve weighting principles differently
under different circumstances if they conflict.
An ethical framework is not an algorithm designed
to recommend a certain course of action based on a
set of variable inputs, but rather it is a tool to encourage
reflection on important ethical concerns to improve
conscientious decision making at every step of the pro-
cess. This framework presents a lean but comprehensive
structure that establishes a minimum ethical threshold
for decision making about CGD use in health care—
an ethical ‘‘safety net.’’ External expert review found
this framework to be comprehensive, able to support
user-specific ethical CGD decision making, and would
assist organizations to safeguard persons and popula-
tions from negative impacts.
Educational and ethical considerations for genetic
test implementation within health care systems
Emma Kurnat-Thoma, PhD, MS, RN, from NIH,
National Institute of Nursing Research (NINR) and
Georgetown University School of Nursing and Health
Studies, presented how the Precision Medicine/
Precision Health (PM/PH) era presents unprece-
dented proliferation of genetic/genomic information
and bioinformatic tools. Commercial sector trends
for genetic test utilization in the U.S. health care system,
health care provider workforce adequacy, genetics/
genomics clinician education and training resources,
and clinical decision support implementation resources
were highlighted.
To ensure safe adoption and clinical translation of
PM/PH, health care systems have an ethical responsi-
bility to ensure their providers and frontline staff are
adequately prepared to order, use, and interpret genetic
test information. Strong partnerships between health
care system leaders, frontline providers, and staff cou-
pled with reasonable goal setting can help drive PM/PH
translation interests.
Day 2 concluded with a stimulating poster session
over wine and cheese. A total of 34 posters covering
six themes were presented. A panel of judges picked
three poster winners who were given award certificates
at the concluding session of the conference.
Day 3: Plenary Talks, Keynote Addresses, Panel
Discussions, and Session Talks
Plenary session 2, address 1: ‘‘Systems thinking
and the U.S. population health ecosystem’’
William Rouse, PhD, from the McCourt School of Pub-
lic Policy at Georgetown University, gave the plenary
talk on the concluding day. He discussed the fragmen-
tation in the U.S. population health delivery systems
and presented key challenges facing U.S. health care
system, including substance abuse and the opioid epi-
demic, and the oncoming volume and complex health
management needs of aging of baby boomers. He high-
lighted use of IT-enabled population health analytics
strategies as a valuable tool to further understand
these health system complexities and predict interven-
tions to bring about their resolution.
The role of assistive technologies for disabled and
older adults to enable information sharing and proper
care coordination will facilitate higher value integrated
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health care. AI-based cognitive assistants will allow for
deeper understanding of work domains and clinical
workflows to better understand the preferences and
needs of patients, disabled, and older adults. He con-
cluded his plenary with a challenge and call for health
care systems to use advanced analytic approaches to
meet these needs.
Plenary session 2, address 2: ‘‘Paradox entails new
kinds of knowledge in medicine and elsewhere’’
Dr. Bruce West, PhD, from the Army Research Office
brought to light the paradox (a logical contradiction)
that exists in the scientific modeling of complex phe-
nomena in physical, social, or life sciences. Specifically,
when paradoxes are encountered that a scientific com-
munity has not yet observed or encountered, how
should conflicting experimental data and theoretical
models be interpreted to understand the differences.
He described ways to resolve this paradox and pre-
sented a new mathematical theory that addresses emer-
gent properties by identifying macro variables for their
description, which are independent of the dynamics of
the micro variables they replace. Dr. West outlined how
the collective behavior captured by the macro variables
is often at variance with the more familiar reductionist
theories with which we are more comfortable. He con-
cludes that the emergent macro behavior resolves para-
doxes and invariably produces a new way of thinking
about familiar phenomena, one that could not be envi-
sioned before the resolution. He showed how the self-
organized temporal criticality model may formally
overcome a paradox by replacing an either/or with a
both/and way of thinking.
Session 4: Drug repurposing
and network medicine
Network medicine: The end of medicine as we know it?
(keynote address). Harald H.H.W. Schmidt, MD, PhD,
PharmD, from Maastricht University presented the con-
ceptual challenges and failures of the pharmaceutical in-
dustry since the 1950s in that most medications failed
to provide a benefit to most patients, a logarithmic decline
in efficacy and poor translation of basic biomedical re-
search into medical applications. One reason for this
was false academic incentives, that is, a focus on high-
impact publications and funding income rather than pa-
tient benefit as ultimate measure of successful biomedical
research. This has led to a lack of quality and reproduc-
ibility of published data, and a positive publication bias.
The biggest challenge that basic and clinical research
needs to overcome is our current concept of a disease.
We must shift our view of diseases from looking at
them within one organ, to looking at them according
to the underlying mechanism of action. He discussed
through examples how Network Medicine will exploit
to mechanism-based redefinitions and endophenotyp-
ing of diseases for network pharmacology, that is, syn-
ergistic combination therapy based on causal signaling
modules. These modules are, however, distinct from
current annotated pathways (e.g., KEGG and Wiki),
which are not much more than mindmaps and not
helpful in defining molecular disease mechanisms.
The key gap is not so much how many drugs will be
able to be repurposed, but the development of precision
diagnostics that allow for low intervention patient strat-
ification. Examples of where this paradigm shift is being
realized include redefinition of cancers, immune dis-
eases, and a cluster of cerebro-cardio-metabolic pheno-
types with clinical proof of concepts underway.
Pathway networks generated from human disease phe-
nome. Maricel G. Kann, PhD, from University of
Maryland Baltimore County presented a pathway-
based approach to extend disease-variant associations
and find new molecular connections between genetic
mutations and diseases.
She used a compilation of > 80,000 human genetic
variants and their associated diseases to normalize
phenotype terminologies in the Unified Medical Lan-
guage System (UMLS). All variants were then grouped
by UMLS Medical Subject Heading (MeSH) identifiers
and enriched for Kyoto Encyclopedia of Genes and
Genome (KEGG) pathways. Linking KEGG pathways
to underlying genetic variations elucidated novel con-
nections with disease phenome and metabolic path-
ways not detectable through gene-level analyses.
Examples included shared mutations between Noonan
syndrome and essential hypertension, and common
pathways in cardiovascular and connective tissue dis-
eases. Identifying novel shared pathways across diseases
constitutes an important contribution to extending
disease-variant connections and provides the foundation
to build novel disease–drug networks for new diagnostic
and therapeutic interventions.
Network-based analysis to prioritize metabolic inter-
ventions in patients with anthracycline-induced cardiac
dysfunction. Feixiong Cheng, PhD, from the Genomic
Medicine Institute, Lerner Research Institute, at the
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Cleveland Clinic, introduced the concept of integrated
network models and analysis to better understand
comorbidity between diseases. Traditional epidemi-
ology research designs are unable to fully account
for the complexity of confounding genetic and en-
vironmental factors. Dr. Feng presented an in-
novative network methodology to understand the
observed comorbidity with cancer treatments, spe-
cifically anthracycline-induced cardiac dysfunction
(doxorubicin). A network-based methodology that
focused on screening, monitoring, and treating
anthracycline-related heart failure was developed.
He presented data from multiomic profiles within an
integrated human protein–protein interactome, includ-
ing transcriptomics from human-induced pluripotent
stem cell-derived cardiomyocytes, metabolomics from
doxorubicin-related cardiac dysfunction in rat models,
and large-scale echocardiogram data from Cleveland
Clinic’s Epic database. Several novel pathways were
identified, such as the AMP-activated protein kinase-
signaling pathway. Highly integrative network ana-
lytic methodologies will allow for rapid identification
and translation of metabolic interventions for
anthracycline-induced cardiovascular complications.
Session 5: Rare diseases and the role
of systems/network medicine
The foundation for rare disease drug development in
the era of systems medicine (keynote address). James
Valentine, JD, MHS, from Hyman, Phelps & McNa-
mara PC, summarized the history and trends in ap-
provals for therapeutic drugs by the U.S. FDA for
the treatment of rare diseases for the past 35 years
to present. Currently, 95% of all rare diseases are with-
out an FDA-approved drug. Because 80% of rare dis-
eases have a genetic origin, Mr. Valentine presented
how Systems Medicine tools could be harnessed to
bridge this gap through advancements in regulatory
science.
He outlined how pioneering work at the U.S. FDA
was being conducted to facilitate patient-focused drug
development. Specifically, innovative regulatory reviews
were conducted with the benefit of patient experience
data—hearing directly from patients and caregivers as
consultants, through patient-focused drug. Develop-
ment meetings, and directly during qualitative video in-
terviews during clinical trials—providing a systematic
approach to ensure the needs of vulnerable patients suf-
fering from rare diseases were met. A review of FDA-
approval summary statistics for rare diseases identified
effective and appropriate regulatory flexibility given the
challenges and hurdles of this field.
Longitudinal profiling of carriers as a key to under-
standing human body homeostasis. Ancha Baranova,
PhD, from George Mason University presented how
traditional genetic analyses using knockout and knock-
down animal models can limit progress in knowledge
discovery due to time requirements and the inability
to replicate findings in humans. High-throughput ge-
nome analysis allows for rapid scanning of individuals
for the activation of a particular gene that can be cor-
related to a detectable phenotype.
Community-wide efforts in building database infor-
mation containing precise genotype–phenotype corre-
lations that are informed by quantified contributions
of incomplete penetrance, haploinsufficiency, and het-
erozygous advantages are key to understanding human
body homeostasis. Longitudinal profiling of parent car-
riers for children with autosomal recessive diseases that
are greatly enriched in heterozygous variants repre-
sents a valuable stakeholder cohort for this effort.
Networks and tools for rare diseases systems medicine
research. Anne Pariser, MD, from the NIH Office of
Rare Disease Research (ORDR) at the National Center
for Advancing Translational Sciences (NCATS) in-
formed the attendees of programs, initiatives, and
tools that are accelerating the development of rare dis-
ease treatments so that no patient is left behind.
ORDR’s programs included the Rare Diseases Clinical
Research Network (RDCRN), which includes 20 cen-
ters of excellence, each of which focuses on three or
more related rare disorders comprising a total of
> 200 different rare diseases.
The RDCRN funds innovative research to further
multidisciplinary investigation of rare disease research,
including natural history studies, clinical trials, and
young investigator awards. The Data Management
and Coordinating Center provides tools and common
processes for the standardized collection of clinical re-
search data for rare diseases. The Genetics and Rare
Diseases Information Center provides clinical trial
readiness grants, gene therapy platforms, in collabora-
tion with the NCATS Therapeutics for Rare and
Neglected Diseases program and microphysiological
system ‘‘tissue chips’’ in the NCATS Division of Pre-
clinical Innovation. They are also solving difficult
translational hurdles and advancing the field of rare
diseases research.
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Patient stories and how they drive systems medicine
research. Christina Grant, MD, PhD, from the Child-
ren’s National Medical Center in Washington, DC,
shared how the most intriguing patient stories can
drive Systems Medicine research. Rare disease medi-
cine faces the difficulty of small patient numbers in
clinical trials, thus obscuring the cause and effective
treatment of a disease.
Knowledge from patient stories coupled with data
from biological systems and use of bioinformatics in
rare disease research can help overcome limitations of
small sample sizes and inform pathophysiology and ther-
apies for more common conditions. Examples include
repurposing a drug used in rare disease for a common
disease based on shared biological networks; using a
common medication to treat a rare disorder; using bioin-
formatics to more rapidly diagnose a rare disorder; and
tailoring therapies based on combined knowledge from
bioinformatics and biological networks.
Jeeva’s AI-based virtual trials site accelerates clinical
trials significantly reduces cost and patient travel
burden. Harsha Rajasimha, PhD, described how his
innovative startup company, JEEVA Informatics Solu-
tions, Inc., used an AI-driven approach to overcome
clinical trial operations obstacles stemming from travel
burden when patients are not physically close enough
to a research investigator to participate in eligibility, re-
cruitment, and enrollment processes. Dr. Rajasimha
outlined how using an AI-based virtual trial site helps
investigators and directors of clinical trials operations
accelerate speed, generate significant cost savings,
and reduce participant travel burden by *80%. Geo-
graphically diverse patients, sponsors, and contract
research organizations can include Jeeva as a virtual
site in addition to brick and mortar sites as an option
for patient participation in clinical trials through use
of a smartphone-based technology platform, eCon-
sent through database lock and study closeout, and
eVisits. Jeeva’s AI engine automatically learns from
past clinical trials to guide and enhance overall suc-
cess probability of future trials.
Panel discussion 2: Current challenges
in health care
The panel was moderated by Dinesh Verma, PhD, Ste-
vens Institute of Technology. Panelists included William
B. Rouse, PhD, Georgetown University, Washington,
DC; Guru Madhavan, PhD, MBA, National Academy
of Engineering, Washington, DC; Dennis McBride,
PhD, SourceAmerica, Vienna, VA; Maeve McKean,
JD/MSFS, Georgetown University Global Health Initia-
tive, Washington, DC; and James C. Palmer, DMan,
Caldwell Palmer, Denver, CO. The diversity of back-
grounds of the panel members provided for a spirited
discussion on domestic and global health and health
care from a variety of points of view.
Professor Rouse stated that harnessing the use of
Population Health principles, which can integrate
health, education, and social services to keep a defined
population healthy, will allow the United States to ad-
dress health challenges holistically and better predict
and support the realities of being mortal. The frag-
mentation of the U.S. health care delivery system is a
formidable challenge, and Professor Rouse identified
elements of the critical infrastructure that will be re-
quired to overcome this, such as strategic IT-enabled
capabilities that foster health information sharing and
patient care coordination. AI-based cognitive assistants
that can provide advanced population analyses will
allow for greater system-level prediction capabilities
for at-risk subpopulations.
Dr. Madhavan remarked that metaphors and models
from systems engineering can fruitfully aid in our un-
derstanding of the ‘‘state’’ of population health and
medical systems. Using these approaches will allow
us to understand both progress and degradations
within the health care system, and to introduce proper
accounting of expenditures and essential accountability
for health outcomes.
Dr. Palmer stated that if he could, he would change
the curriculum at all medical schools to include a focus
on systems thinking and complexity science. He high-
lighted that although many speakers showed new ways
to identify diseases (e.g., the notion of pathways),
today, we lack a theory of humans as organisms.
When we think of organizations, or extended organiza-
tions with distributed governance, they need to have
the critical capability of self-awareness as a prerequisite
to change.
Maeve McKean spoke to the closing gap between
global health and domestic health. Drawing on the
World Health Organization’s Ten Threats to Global
Health in 2019, Ms. McKean noted that for a majority
of the burdens experienced by low-income countries
were shared just as greatly by high-income ones.
Examples included how both share the short- and
long-term health effects of air pollution and climate
change, changing demographics involving noncom-
municable diseases, and the growing struggle with
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vaccine hesitancy. For each of these and others on the
list, the ‘‘solution’’ requires shared partnerships and
concerted attention from those within our own local
and national health system, to engage in and develop
structures for global information sharing and best
practice implementation.
Dr. McBride questioned the rather universally ac-
cepted view that there actually is a medical or health
care system—at least as systems scientists define sys-
tems. Properties of systems include regularity and
order in the variables/relationships among inputs and
outputs. In other words, systems are organizations of
predictable feedback and feedforward systems. Many
such systems adapt or learn. Dr. McBride believes
that ‘‘health care’’ does not seem to align readily with
these characteristics. However, if we use the taxonomy
and methodology of complex adaptive systems, health
care would be described as a wicked system.
A characteristic of such systems is that when at-
tempts are made to ‘‘improve’’ system level perfor-
mance, the treatment actually renders the system
more complex, less predictable, and further degraded.
Alternatively, we can use simplifying assumptions
about key subsystems in the health care complex.
This allows us to focus on problems such as diagnostic
errors, which are cited as the third leading cause of
death in the United States, and thus a legitimate inter-
vention target. In this way, we can apply rigorous iden-
tification and examination of the patterns of subsystem
interplay—and emergence—that in effect incubate di-
agnostic errors. Dr. McBride argued that there has
been a paucity of examination of diagnostic error pro-
duction at this level. There is an abundance of organiza-
tional systems learning science that can be applied
toward improvements in diagnosis accuracy—that is,
in the reduction of type I and type II errors, and the im-
provement of diagnostic timeliness.
Session 6: AI/deep learning in medicine
and natural language processing
Precisely practicing medicine from 700 trillion points of
data (keynote address). Atul J. Butte, MD, PhD, is the
director of the Bakar Computational Health Sciences
Institute, University of California San Francisco and
chief data scientist for the entire University of Califor-
nia Health System (UC Health). Dr. Butte’s laboratory
builds and applies tools that convert ‘‘big data’’—or tril-
lions of points of molecular, clinical, and epidemiolog-
ical data—measured by researchers and clinicians into
diagnostics, therapeutics, and new insights into disease.
He presented how use of publicly available molecular
measurements can be used to find new uses for drug
therapies for autoimmune diseases and cancer; how
big data can be mined for new ‘‘druggable’’ targets in
disease; how to evaluate patients and populations pre-
senting with whole-genome sequence data; integrating
and reusing clinical and genomic data from clinical tri-
als; discovery of new diagnostics for pregnancy compli-
cations; and most inspiringly, how the next biotech
startup could come from your garage.
Learning to predict critical outcomes in the intensive
care unit: The safe-intensive care unit perspec-
tive. Tavpritesh Sethi, MBBS, PhD, stated that a new
machine learning article is published every 20 min,
yet a small fraction of these articles impact patient
care processes at the bedside. Dr. Sethi’s research out-
lined his group’s work to bridge this gap with Meaning-
ful Enriching and Discovery-led AI for intensive care
units (ICUs).
He presented case study data from predictive models
for the ICU and public health settings, including the
creation of Sepsis Advanced Forecasting Engine-ICU,
the largest pediatric big data resource at All India Insti-
tute of Medical Sciences, New Delhi, India. The devel-
opment of wiseR, an interpretable and interactive AI
platform for constructing BDNs was highlighted, in
addition to summaries of case studies for antimicro-
bial resistance and maternal health. Insights from
these studies can inform future AI efforts in medicine
to decrease U.S. health inequalities.
AI in radiological imaging: Lesson learned and possible
roadmap ahead. Seong K. Mun, PhD, is a professor of
physics from Virginia Tech, and director, Arlington
Innovation Center for Health Research (Virginia
Tech). During the past 30 years, radiology science de-
veloped computer-aided diagnosis using convolution
neural networks (CNNs) before AI was a popular
field. CNNs are a category of neural network algo-
rithms that can take in images and assign weights
and balances to various objects comprising the image
to differentiate outputs.
Although the full potential of AI in imaging and in-
formatics has yet to be realized, it is generating signif-
icant interest. Dr. Mun highlighted three primary
obstacles to widespread use of AI in radiological prac-
tice: (1) current machine learning algorithms with
CNN tools are based on handwriting and general im-
ages; however, radiology images require differentiation
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of subtle gray value features within local areas; (2) to
build a usable CNN tool, a massive clinically represen-
tative data base with ground truths for extensive train-
ing and validation is required, but is extremely
expensive to develop; and (3) the CNN tools in re-
search settings do not translate easily into clinical set-
tings and must take local clinical practice patterns
and workflows into account.
Conference Conclusion
Closing remarks and comments to the conference were
provided by Dr. Harald H.H.W. Schmidt, MD, PhD,
PharmD, who outlined key takeaways and highlights
from the 3 days that spanned: Systems Medicine sci-
ence, health care policy and health care system infra-
structure, ethical legal and social considerations,
health care provider education and training frame-
works, population health analytics, clinical trial infra-
structure, legal and regulatory considerations for drug
development and technological innovations, big data,
AI and machine learning.
Dr. Schmidt closed with a rousing invitation for at-
tendees to attend the second international Systems
Medicine conference held on March 18–20, 2020, in
Munich Germany, and for presenters to consider sub-
mitting written work to the peer-reviewed journal Sys-
tems Medicine. The session concluded with final
attendee comments, question/answer dialogue, and
networking between speakers and attendees.
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RCSB PDB¼ Research Collaboratory for Structural Bioinformatics
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